Cramer's Mad Dash: Bristol Myers
CNBC's Jim Cramer breaks down why he's keeping an eye on shares of Bristol Myers. Irv Gotti, Music Executive Behind Ja Rule ...
Trade Tracker: Josh Brown sells Bristol Myers after buying it on Monday
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Bristol Myers so ...
Jim Cramer on Bristol-Myers Squibb (BMY): “First Schizophrenia Drug in 30 Years”
We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks. In this ...
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...
NBC New York22d
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
But Alzheimer's is the "really large market here," Bristol Myers Squibb CFO David Elkins told CNBC on Tuesday at the JPMorgan Health Care Conference in San Francisco. There are nearly 6 million ...
Business Insider23d
Bristol Myers CEO says new drug Cobenfy effective in schizophrenia, CNBC reports
Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older therapies, writes Julie Coleman for CNBC..Bristol ...